NIH to Spend Full $48.7B Budget Despite Grant Award Slowdown | STAT

National Institutes of Health Director Dr. Jay Bhattacharya assured House lawmakers on Tuesday that the agency will spend its entire $48.7 billion budget for the 2026 fiscal year, despite a significantly slower pace of grant awards compared to recent years. The commitment comes amid scrutiny over delays in funding biomedical research, raising concerns that unused funds could be returned to the treasury.

Data presented to the House Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies revealed that, roughly halfway through the fiscal year, the NIH has awarded 74% fewer competitive, or new, research grants than the average between 2021 and 2024. This slowdown has prompted questions from both Republicans and Democrats about the agency’s efficiency and its impact on the scientific community. Bhattacharya, who is also currently serving as acting director of the Centers for Disease Control and Prevention, addressed these concerns directly during the oversight hearing.

Grant Disbursements and Congressional Scrutiny

The lag in grant disbursements has been particularly noticeable in competitive awards, which fund innovative research projects proposed by scientists across the country. Johns Hopkins researchers analyzed the data, highlighting the substantial decrease in new awards. Even as the total budget remains substantial, the slower rate of spending has fueled anxieties about potential disruptions to ongoing research and the ability of the NIH to meet its long-term goals. STAT News reports on the details of the funding slowdown.

Bhattacharya’s appearance before Congress marked his first since being appointed acting CDC director by President Donald Trump last month, adding another layer of complexity to his role. This dual leadership position comes after a period of turmoil at the CDC, following the firing of its Senate-confirmed director last summer by Health and Human Services Secretary Robert F. Kennedy Jr. Due to disagreements over vaccine policy. Kennedy’s stance on vaccines has reportedly contributed to a decline in public trust in public health agencies, including the CDC and the Food and Drug Administration.

A Dual Role: NIH and CDC Leadership

Dr. Jay Bhattacharya’s journey to leading both the NIH and, in an acting capacity, the CDC is rooted in his background as a physician-scientist and health economist. According to his Wikipedia profile, he earned his M.D. And Ph.D. In economics from Stanford University and previously served as a professor of medicine, economics, and health research policy at the same institution. He was appointed as the 18th Director of the National Institutes of Health in April 2025 by President Trump and confirmed by the Senate in March 2025, becoming the first Indian American to hold the position.

Bhattacharya’s research has focused on the economics of healthcare, and he is known for his opposition to the widespread lockdowns and mask mandates implemented during the initial stages of the COVID-19 pandemic. His appointment to lead the NIH and now to also oversee the CDC reflects a shift in priorities within the administration, potentially signaling a greater emphasis on economic considerations and a reevaluation of public health strategies.

Addressing Concerns About Budget Utilization

During the House Appropriations hearing, Bhattacharya repeatedly emphasized the NIH’s commitment to fully utilizing its $48.7 billion budget. He acknowledged the slower pace of grant awards but assured lawmakers that the agency is taking steps to accelerate the process and ensure that funds are allocated efficiently. He did not detail specific measures being taken to expedite grant disbursements, but indicated that the agency is working to address administrative bottlenecks and streamline the application review process.

The NIH funds basic science research at universities and institutions nationwide, which is crucial for advancing biomedical research and pharmaceutical development. Delays in funding can have a cascading effect, potentially slowing down the progress of important research projects and hindering the development of new treatments and therapies. The agency’s ability to effectively manage its budget and ensure timely funding is therefore critical to maintaining the momentum of scientific innovation.

The Impact of Vaccine Skepticism on Public Health Trust

The situation at the CDC, with its recent leadership changes and the influence of Secretary Kennedy’s vaccine skepticism, adds another layer of complexity to the public health landscape. The Washington Examiner reports that Kennedy’s decisions regarding vaccines have led to a noticeable decline in trust in public health institutions. This erosion of trust could have significant implications for public health initiatives, such as vaccination campaigns and disease surveillance programs.

Maintaining public trust is essential for the effective implementation of public health measures. When individuals lose faith in public health agencies, they may be less likely to follow recommended guidelines or participate in public health programs, potentially increasing the risk of disease outbreaks and other health crises. Rebuilding trust will require transparency, clear communication, and a commitment to evidence-based decision-making.

Looking Ahead: Grant Processes and Agency Priorities

The NIH is currently reviewing its grant application and review processes to identify areas for improvement. This review is expected to focus on streamlining administrative procedures, reducing bureaucratic hurdles, and ensuring that grant applications are evaluated fairly and efficiently. The agency is also working to prioritize research areas that align with its strategic goals, such as cancer research, Alzheimer’s disease, and emerging infectious diseases.

Bhattacharya’s commitment to spending the full budget by the end of the fiscal year will be closely watched by the scientific community and lawmakers alike. The agency’s ability to deliver on this promise will be a key indicator of its effectiveness and its commitment to supporting biomedical research. Continued oversight from Congress will be crucial to ensure that the NIH remains accountable and transparent in its operations.

The agency will also be navigating the challenges of maintaining public trust in the face of growing vaccine skepticism and political polarization. Bhattacharya’s leadership will be tested as he seeks to balance the require for scientific rigor with the demands of political accountability and public perception. The coming months will be critical in shaping the future of the NIH and the CDC, and their ability to effectively address the nation’s most pressing health challenges.